Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Pfizer ( PFE, Financial) stock dropped more than 2% at the start of the stock market opening Tuesday after the company posted ...
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...
Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback